Navigation Links
Asmacure Ltee Issued Patent to Govern Composition-of-Matter for its Nicotinic Receptor Technology in the U.S.

QUEBEC CITY, Oct. 25, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that it has been issued U.S. patent No. 8,039,459 from the United States Patent & Trademark Office (USPTO) entitled "Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases."  The first patent of this series in the USPTO comprises compounds and pharmaceutical composition claims.

"The issuance of these patents in the U.S. and Japan are important developments for the strong global intellectual property estate for our lead compound, ASM-024," said Mr. Martin Driscoll, CEO of Asmacure. "This important expansion of the patent protection for ASM-024 is another milestone in the development of our proprietary new mechanism for the treatment of asthma and other respiratory inflammatory diseases."

The nicotinic receptor agonist compounds developed for the treatment of pulmonary inflammatory diseases were discovered at the Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Quebec, a research center affiliated with Universite Laval. Asmacure has an exclusive license from Universite Laval to develop and commercialize any product derived from this technology.

On July 15, 2011, the Japan Patent Office issued the corresponding Japanese patent No. 4783787.  The claims within the patent are directed to compounds as well as pharmaceutical compositions for treating or preventing pulmonary inflammatory diseases.

About Asmacure

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases. The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma. ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada. The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec. For more information visit

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach,
Claire Sojda,

SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asmacure Ltee to Present at the 2011 BIO Business Forum During the Annual BIO International Convention
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
4. Urgent Call Is Issued for More Local Doctors and Nurses for Mondays Free Health Clinic
5. U.S. Patent for Leatt Neck Brace System Issued
6. China Medical Technologies Announces the First Inclusion of FISH Tests for Diagnosis of Certain Hematological Malignancies in the Clinical Guidelines Issued by the MOH
7. PRA Experts Pulmonary Function Textbook Reissued
8. Voluntary Worldwide Field Correction Issued for the S98/98XT, CS100/CS100i and CS300 Intra-Aortic Balloon Pumps
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Landmark Patents Issued for ViewRay Technology
11. Two New U.S. Patents Issued to Dyadic International
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):